Resonance Health Limited (ASX: RHT), an Australian healthcare technology and services company providing quantitative medical imaging analysis globally for disease management and pharmaceutical clinical trials, recently held its 2026 Annual General Meeting (AGM). Chairperson Mr. Aaron Brinkworth and Managing Director & CEO Mr. Andrew Harrison addressed shareholders, highlighting a significant and successful financial year 2026 (FY26). The company reported a substantial 42% increase in revenue, reaching $15.8 million, and returned to profit with a net profit after tax of $1.5 million. This turnaround from a prior-year loss of $1.7 million underscored Resonance Health’s strategic success, with operations generating positive cash flow quarterly.
Mr. Harrison detailed that robust performance was propelled by tailwinds including rising liver disease, approved MASH therapies, and a surge in GLP-1 and obesity clinical trials requiring precise imaging. The company’s integrated “three oars in one boat” model, encompassing Resonance Imaging, Resonance Clinical (its Contract Research Organisation), and TrialsWest investigator sites, proved effective. Imaging revenue from clinical trials surged 88%, while CRO revenue grew 81%. To accelerate growth, particularly in the obesity-trial market, and advance its liver fibrosis device, Resonance Health undertook a $6 million placement in October for these strategic programs and planned expansion of TrialsWest sites to Australia’s east coast.
Looking ahead, Resonance Health unveiled its FY27 guidance, projecting revenue between $17 million and $22 million and normalised EBITDA of $2.6 million to $3.6 million. This guidance conservatively excludes potential contributions from its liver fibrosis device, future acquisitions, or further geographic expansion. The company remains focused on developing its pipeline, with preliminary results from its MRI liver fibrosis device showing promising accuracy, and completing a new MRI muscle volume and quality endpoint for obesity trials. Management reiterated its commitment to sustained, profitable growth, aiming for $50 million in revenue by end of FY28, which is expected to include strategic acquisitions.
